Tim Boreham: ASX tech throwing light on deadly mystery

A US military-inflicted blight on American service personnel has left an ASX stock with important – and lucrative – work to do, reports Tim Boreham.

4D Medical is giving doctors a clear view of lung damage (image for illustration purposes only). Picture: iStock

Joe Biden this week might have snubbed our leaders in favour of dealing with a wee $US31 trillion ($47 trillion) debt issue at home, but lung imaging house 4D Medical (ASX:4DX) still has 420 billion reasons to call POTUS a buddy.

That’s because Congress has allocated a stupendous $US280 billion to deal with the “new Agent Orange” – the scandalous legacy of burn pits used by the US military in Afghanistan and Iraq.

---

For the best columnists, sign up here for free Stockhead daily newsletters

---

Super-sized versions of Dad’s belching 1970s backyard incinerator, these cavities would combust anything from computers to uniforms, medical and human waste.

They also damaged the lungs of those in the vicinity and now something is going to be done about it at last.

Allocated over 10 years, the spending is classed as mandatory and can’t be part of debt ceiling cost-cutting negotiations.

A key proponent of the relief measure, Biden believes the toxic emissions from burn pits might have contributed to the glioblastoma that killed his serving son Beau.

The burn pits were used because destroying disc drives and uniforms in situ was cheaper than shipping them home and was better than leaving them for the local insurgents.

“About 3.5 million US soldiers have been exposed to burn pits and it has damaged the lungs of hundreds of thousands of them, giving them a mystery disease that doesn’t show up in CT scans, X-rays or pulmonary function tests,” says 4D chief Andreas Fouras.

---

MORE TIM BOREHAM: What’s fuelling buyout frenzy?| Old King Coal a profitable soul | ASX firms leading cancer fight

---

The disease has been dubbed “post-deployment respiratory syndrome”.

The burn pit package stipulates the use of “four-dimensional models of lung function”.

As it happens, 4D Medical is the world’s only dedicated provider of 4D lung imaging, via its algorithm-based software.

Fouras says that detecting the fine particles in the lung currently requires a surgical biopsy: cutting through the ribs and extracting a sample in three places.

The pain factor and the three-day hospital stay aside, the tests cost $US15,000 a pop.

This month, 4D carried out its first commercial veterans scan, at the Harry S Truman Memorial Veterans Hospital in Columbia, Missouri.

The company hopes to sign up more of the 170 veteran care facilities, which collectively are bigger than the entire Australian hospital system.

Advised by former Department of Veterans Affairs secretary Dr David Shulkin, 4D reps have been schmoozing with key congressmen and veterans’ advocates in view of an all-in-one deal.

---

Visit Stockhead, where ASX small caps are big deals

---

As a rule of thumb, Fouras says, diagnostics account for about 4 per cent of healthcare.

“On that sum 4D still has an addressable market of $US11 billion over 10 years, just in the burn pit money,” he said.

The company is also angling for US insurance reimbursement of about $US200 a test, which would open up a broader market for screening the broader populace.

The US respiratory diagnostic market is estimated at $US13.7 billion a year, with 74 million tests carried out.

Coincidentally, ASX peer Cyclopharm (ASX:CYC) has been waiting for three decades for the US Food and Drug Administration to approve its nuclear imaging agent, Technegas, for pulmonary embolism detection.

Already used in 64 countries including Australia, Technegas promises safer and more thorough treatment in any part of the lung the oxygen (and the gas) reaches.

This column does not constitute financial product advice. You should obtain independent advice before making any financial decisions.

Get more Tim Boreham wisdom at stockhead.com.au

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox. Click here

Originally published as Tim Boreham: ASX tech throwing light on deadly mystery